Engineering B Cells to Produce Therapeutic Proteins

Sean Ainsworth, CEO of Immusoft, about MPS I, the limits of existing enzyme replacement therapies, and the potential benefits of using engineered B cells to treat people with the rare lysosomal storage disorder and other conditions.